Latrodectism
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Rare Disease TherapeuticsTN - Franklin
2 programs1
1
AnalatroPhase 31 trial
ANAWIDOW [antivenin latrodectusPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Rare Disease TherapeuticsAnalatro
Rare Disease TherapeuticsANAWIDOW [antivenin latrodectus
Clinical Trials (2)
Total enrollment: 76 patients across 2 trials
Black Widow Spider Antivenin for Patients With Systemic Latrodectism
Start: Oct 2009Est. completion: Oct 201460 patients
Phase 3Completed
Pharmacokinetic Study Protocol of ANAWIDOW Lyophilized Powder for Solution for Intravenous Use in Fasting Conditions
Start: Jul 2021Est. completion: Feb 202216 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.